Lebrikizumab for nummular eczema in adults
Treatments studied
Part of Skin clinical trials.
This study tests whether lebrikizumab, a new injection, can reduce nummular eczema (coin-shaped eczema patches) in adults whose condition hasn't improved with topical steroid creams. It's designed to help people with moderate-to-severe nummular eczema who need a stronger treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with nummular eczema (coin-shaped eczema patches) for at least 6 months
- Your nummular eczema has not improved adequately with topical steroid creams
- You have not previously taken lebrikizumab, dupilumab, tralokinumab, or Janus kinase inhibitors for eczema
- You do not have moderate-to-severe atopic dermatitis (general eczema) at the same time as nummular eczema
- You do not have other active skin conditions like psoriasis or other forms of eczema that could interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injected medicine, lebrikizumab, for people whose eczema mainly affects the face and neck. It aims to see if it can improve these hard-to-treat areas.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests how well lebrikizumab (Ebglyss), an approved treatment for moderate-to-severe atopic dermatitis (eczema), works in everyday clinical practice. It aims to see how the drug affects your symptoms and quality of life over time, helping guide better treatment decisions.
This study tests a drug called lebrikizumab for people with severe prurigo nodularis, a condition with very itchy skin bumps. The drug is given as an injection and aims to reduce itching and clear the bumps faster.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
Hear when a new Nummular Eczema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.